Skip to main content
SpringerLink
Log in

Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Objective

To determine which Thyroglobulin (Tg) level after levothyroxine (LT4) withdrawal (stimulated thyroglobulin - sTg) measured before radioiodine therapy (RAIT) is able to predict incomplete response to treatment of differentiated thyroid carcinoma (DTC) with greater sensitivity and specificity one year after initial treatment with I131.

Methods

A chart review was performed in which 375 patients with DTC treated with RAIT were included. The sTg was measured in all patients prior to treatment with I131. Follow up were then performed one year later. Initial sTg levels were associated to DTC outcomes. A receiver operating characteristic (ROC) curve was performed to achieve a sTg level able to predict which patients would have a greater chance of having an incomplete response to RAIT.

Results

Incomplete response to treatment was found in 122 patients (32.5%), this group had a mean sTg of 23.2 ng/mL. ROC curve showed that the optimal cut-off sTg level was 4.4 ng/mL. (sensitivity: 72.1%; specificity: 72.3%; accuracy: 72.2%; positive predictive value of 55.7%; and negative predictive value: 84.3%).

Conclusion

sTg pre-ablation is a valuable predictor of DTC incomplete response to treatment one year after RAIT. Levels of 4.4 ng/ml or more showed higher accuracy to predict this outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data sheet is available for consultation.

References

  1. B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, Mandel et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016). https://doi.org/10.1089/thy.2015.0020

    Article  PubMed  PubMed Central  Google Scholar 

  2. P.W. Rosário, L.S. Ward, G.A. Carvalho, H. Graf, R.M. Maciel, L.M. Maciel, A.L. Maia, M. Vaisman, Nódulo tireoidiano e câncer diferenciado de tireoide: atualização do Consenso Brasileiro. Endocrinol Metab 57, 240–264 (2013). https://doi.org/10.1590/S0004-27302013000400002

    Article  Google Scholar 

  3. F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, W. Wiersinga, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154, 787–803 (2006). https://doi.org/10.1530/eje.1.0258

    Article  CAS  PubMed  Google Scholar 

  4. R.M. Tuttle, R. Leboeuf, Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 37, 419–435 (2008). https://doi.org/10.1016/j.ecl.2008.02.008

    Article  PubMed  Google Scholar 

  5. F. Pacini, Follow-up of differentiated thyroid cancer. Eur J Nucl Med 29, S492–S496 (2002). https://doi.org/10.1007/s00259-002-0847-9

    Article  Google Scholar 

  6. M. Spaas, B. Decallonne, A. Laenen, J. Billen, S. Nuyts, Prognostic value of stimulated thyroglobulin levels at the time of radioiodine administration in differentiated thyroid cancer. European thyroid journal 7, 211–217 (2018). https://doi.org/10.1159/000489849

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. J. Jayasekara, P. Jonker, J.F. Lin, A.F. Engelsman, M.S. Wong, S. Kruijff et al. Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer. Surgery 167, 40–45 (2020). https://doi.org/10.1016/j.durg.2019.06.048

    Article  PubMed  Google Scholar 

  8. R.C. Webb, R.S. Howard, A. Stojadinovic, D.Y. Gaitonde et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab 97, 2754–2763 (2012). https://doi.org/10.1210/jc.2012-1533

    Article  CAS  PubMed  Google Scholar 

  9. R.M. Tuttle, H. Tala, J. Shah et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010). https://doi.org/10.1089/thy.2010.0178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Amin, M.B., Edge, S., Greene, F., Byrd, D.R., Brookland, R.K., Washington, M.K., Gershenwald, J.E., Compton, C.C., Hess, K.R., et al. (Eds.). AJCC Cancer Staging Manual (8th edition). Springer International Publishing: American Joint Commission on Cancer (2017).

  11. M. Melo, G. Costa, C. Ribeiro et al. Stimulated thyroglobulin at recombinant human tsh-aided ablation predicts disease-free status one year later. J Clin Endocrinol Metabol 98, 4364–4372 (2013). https://doi.org/10.1210/jc.2013-2267

    Article  CAS  Google Scholar 

  12. J.I. Lee, Y.J. Chung, B.Y. Cho, S. Chong, J.W. Seok, S.J. Park, Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. Surgery 153, 828–835 (2013). https://doi.org/10.1016/j.surg.2012.12.008

    Article  PubMed  Google Scholar 

  13. P.W. Rosario, A.C. Xavier, M.R. Calsolari, Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21, 49–53 (2011). https://doi.org/10.1089/thy.2010.0145

    Article  PubMed  Google Scholar 

  14. F. Pitoia, E. Abelleira, G. Cross, Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH. Endocrine 55, 200–208 (2017). https://doi.org/10.1007/s12020-016-1104-5

    Article  CAS  PubMed  Google Scholar 

  15. A. Kelly, B. Barres, F. Kwiatkowski et al. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients. PloS one 14, 8 (2019). https://doi.org/10.1371/journal.pone.0221298

    Article  CAS  Google Scholar 

  16. A. Campennì, R.M. Ruggeri, M. Siracusa et al. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients. Eur J Nucl Med Mol Imaging 48, 2466–2475 (2021). https://doi.org/10.1007/s00259-020-05153-7

    Article  CAS  PubMed  Google Scholar 

  17. P.G.C. Trevizam, J.V. Tagliarini, E.C. Castilho et al. Thyroglobulin levels and thyroglobulin/thyrotropin ratio could predict the success of the ablative/therapeutic 131I in the differentiated thyroid cancers. Endocrine Res. 42, 42–48 (2017). https://doi.org/10.3109/07435800.2016.1173056

    Article  CAS  Google Scholar 

  18. A. Piccardo, F. Arecco, S. Morbelli, P. Bianchi et al. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levothyroxine suppressive treatment in low-risk differentiated thyroid cancer. J Endocrinol Invest 33, 83–87 (2010). https://doi.org/10.1007/BF03346558

    Article  CAS  PubMed  Google Scholar 

  19. T.Y. Kim, W.B. Kim, E.S. Kim et al. Serum thyroglobulin levels at the time of 131 I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90, 1440–1445 (2005). https://doi.org/10.1210/jc.2004-1771

    Article  CAS  PubMed  Google Scholar 

  20. F. Pitoia, M.F. Bueno, E. Abellera, M.E. Salvai, L. Bergoglio, M. Luster, H. Niepomniszcze, Undetectable pre-ablation thyroglobulin levels in patients with differentiated thyroid cancer: it is not always what it seems. Arq Bras Endocrinol Metabol 57, 300–306 (2013). https://doi.org/10.1590/S0004-27302013000400004

    Article  PubMed  Google Scholar 

  21. D. Albano, M. Bonacina, R. Durmo et al. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer. Endocrine 68, 124–131 (2020). https://doi.org/10.1007/s12020-019-02148-9

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Department, Paraíba Federal University (UFPB), João Pessoa, Paraíba, Brazil

    Giulliana Nóbrega

  2. Medical Sciences Department, Pernambuco Federal University (UFPE), Recife, Pernambuco, Brazil

    Milena Cavalcanti

  3. Clinical Medicine Department, Clinical Hospital, UFPE, Recife, Pernambuco, Brazil

    Verônica Leite

  4. Chief Of The Endocrinology Department, Clinical Hospital, UFPE, Recife, Pernambuco, Brazil

    Lúcio Vilar

  5. Chief Of Nuclear Medicine Service, Clinical Hospital, And Associated Medicine Professor, UFPE, Recife, Pernambuco, Brazil

    Simone Cristina Soares Brandão

Authors
  1. Giulliana Nóbrega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Milena Cavalcanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Verônica Leite
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lúcio Vilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Simone Cristina Soares Brandão
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulliana Nóbrega.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethics

This research project was approved by the Ethics Committee of Universidade Federal de Pernambuco – Centro de Ciências da Saúde (2015).

Informed consent

Written consents were obtained from each patient.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nóbrega, G., Cavalcanti, M., Leite, V. et al. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine. Endocrine 76, 642–647 (2022). https://doi.org/10.1007/s12020-022-03021-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-022-03021-y

Keywords

Search

Navigation